Challenges and innovations in MASLD and T2DM: Strengthening personalized medicine with SGLT2 inhibitors: Editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”
Abstract
Challenges and innovations in MASLD and T2DM: Strengthening personalized medicine with SGLT2 inhibitors: Editorial on "Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis"
Fields of Study & Subjects
Liver Disease Diagnosis and Treatment
Diabetes Treatment and Management
Chronic Kidney Disease and Diabetes
Publication details
- Journal / source
- Clinical and Molecular Hepatology
- Volume
- 32
- Issue
- 3
- Pages
- 1417–1420
- Publication date
- 27 January 2026
- Language
- EN